| ²é¿´: 759 | »Ø¸´: 5 | ||||
[½»Á÷]
°ïæ¿´¿´ÓйØÑо¿µ°°×ÖÊÏ໥×÷ÓõķÖÎö·½·¨ÎÊÌâ
|
||||
|
Ê×ÏÈÉùÃ÷£¬±¾È˲»¶®ÉúÎïѧ£¬ËùÒÔÎÄÏ×ÖÐÓйØÊµÑé·½·¨µÄÆðʼ¾ä²»Ì«Ã÷°×¡£ 1To determine whether the compounds inhibited bromodomain-histone binding we utilized a peptide displacement assay based on AlphaScreen technology. Õâ¾ä»°ÖУ¬Ö÷ÒªÊDzÉÓá°Ê²Ã´·½·¨£¿ÉúÎïµÄ²»¶®£¬Çë¸øÓë½âÊÍ¡±²â¶¨»¯ºÏÎïÒÖÖÆäåÓòµ°°×-×é°±ËáµÄ½áºÏ×÷Óᣠ2 to investigate the selectivity of these compounds against other bromodomain, we employed a binding assay based on protein stablity shift. Õâ¾ä»°£¬ÒÀ¾ÉÊǺó°ë¾ä£¬ÉúÎïѧµÄ·ÖÎö·½·¨£¬²»¶®£¬ÐèÒª¸÷λ°ïÎÒɨä¡£ 3 To order to confirm that the dimethylisoxazole moiety was acting as a KAc minic and to elucidate structure-activity profiles for these compounds , we obtained the cocrystal structures of -------. Õâ¾ä»°¾ÍÊÇKAcÊÇɶËõд°¡¡£ ÁíÍ⣬ÓйضԵ°°×ÒÖÖÆ×÷ÓõÄ×ø±êͼÖУ¬ Y-×ø±ê£¨RLUs£©ºÍX-×ø±ê(Dose)·Ö±ð´ú±íʲôº¬Ò壬ͼÌù²»ÉÏÈ¥°¡¡£ |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
·Ö×ÓÉú»¯ÊµÑé¾Ñé»ýÀÛ |
» ²ÂÄãϲ»¶
²»ºÏÀíÍÜ¿ÆÑÐʵÑé֮СÊóʵÑ飺ÑϽ÷Éè¼Æ£¬½âÎöÉúÃü»úÖÆµÄÖØÒªÔØÌå
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®ÖØ½ðÊô¼ì²â£º¾«×¼É¸²é£¬ÊØ»¤½¡¿µÓë»·¾³µÄ·ÀÏß
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ91È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÍܲâÖØ½ðÊôÎÒ±³¹øÈýǧ¡±
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÊóÌÓÈý´ÎÎÒ·¢ÈýƪSCI¡±
ÒѾÓÐ0È˻ظ´
ÄÉÃ×Á£¶È·ÖÎö
ÒѾÓÐ3È˻ظ´
ÁÖ¿ÆÔºÁÖ»¯ËùÕÐÊÕ²ÄÁÏÓ뻯¹¤×¨ÒµË¶Ê¿£¬×ø±êÄϾ©
ÒѾÓÐ0È˻ظ´
Áôѧ--²©Ê¿ÕÐÉú
ÒѾÓÐ16È˻ظ´
»¯Ñ§¹¤³Ì£¬±¾211£¬Çóµ÷¼Á£¬abÇø²»ÏÞ
ÒѾÓÐ4È˻ظ´
ÉÛÑôѧԺʳƷÓ뻯ѧ¹¤³ÌѧԺ˶ʿµ÷¼Á
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
µ°°×ÖÊÖ®¼äÏ໥×÷ÓõÄÑо¿·½·¨ÓÐÄÄЩ£¿
ÒѾÓÐ3È˻ظ´
ÄÄλ°ï°ïæ°¡£¿¹ØÓÚµ°°×µÄÎÊÌâ
ÒѾÓÐ5È˻ظ´
Çë´ó¼Ò°ïæ¿´¿´Îҵĵ°°×µçӾͼ£¬Ð»Ð»´ó¼ÒÁË
ÒѾÓÐ10È˻ظ´
ϸ°ûÄÚµ°°×ÖʵÄÇ×ÊèË®ÐÔµÄÎÊÌ⣬´ó¼ÒÀ´°ïæ¿´¿´¡£
ÒѾÓÐ7È˻ظ´
Ô²¶þÉ«Æ×¶Ô·ÖÎöµ°°×ÖÊÏ໥×÷ÓÃÓаïÖúÂð
ÒѾÓÐ5È˻ظ´
¹ØÓÚE-tag±ê¼Çµ°°×µÄ´¿»¯ÎÊÌ⣡~ÇóÖú£¬Ð»Ð»°ïæ~£¡
ÒѾÓÐ9È˻ظ´
´óϺÃǰïæ¿´¿´3ºÍ4ÕâÁ½¸öµ°°×ÓÃʲôÑùµÄÖù×ÓÌîÁÏÄÜ·Ö¿ª
ÒѾÓÐ10È˻ظ´
°ïæ¿´¿´Éó¸åÒâ¼û£ºÓйطÖ×Ó¶¯Á¦Ñ§Ä£Äâ½âÊ͵°°×Óëµ×ÎïÏ໥×÷ÓÃ
ÒѾÓÐ3È˻ظ´
µ°°×ÖÊÏ໥×÷Óã¿
ÒѾÓÐ4È˻ظ´
´ó¼Ò°ïæ·ÖÎöÒ»ÏÂÎҵĵ°°×´¿»¯Ê±³öÏÖµÄÎÊÌâ°É£¬²»Ê¤¸Ð¼¤
ÒѾÓÐ5È˻ظ´
Çóµ°°×ÖÊÏ໥×÷ÓÃÑо¿·½·¨...
ÒѾÓÐ12È˻ظ´
µ°°×²¹²Ð»ù£¬¸÷λ°ï°ï濴ϰ¡£¡
ÒѾÓÐ11È˻ظ´
¡¾ÇóÖú¡¿¼¦µ°µÄµ°°×ÖÊŨ¶ÈÎÊÌ⣡£¡¸÷λ´óÏÀÇë°ï棡£¡
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿¹ØÓÚQÖù·ÖÀëµ°°×µÄÎÊÌâ~¸ßÊÖ°ï°ïæ~
ÒѾÓÐ7È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
»ù½ðÆí¸£
+3/1673
¡¾Ç¿ÍÆ£ü¿ÉÁôУ¡¿¼ÃÄÏ´óѧ²©Ê¿ºóÕÐÆ¸£¨Ë®Àû¹¤³Ì/ÌúÃÌ̼»·¾³¹ý³Ì£©
+1/287
¡¾ÕÐÆ¸¡¿ÎÂÖÝÒ½¿Æ´óѧ/¸½ÊôÒ½Ôº/걽ʵÑéÊÒÀîУˆÒԺʿÍÅ¶Ó³ÏÆ¸²©Ê¿ºóºÍ¿ÆÑÐÈËÔ±
+1/192
Âí¶ûÎ魯âÁ£¶È+ÄÉÃ×Á£¾¶Zetaµçλ²âÊÔÔʼÊý¾ÝÓëOrigin»æÍ¼V131/2039/8821
+1/90
×ÊÔ´Óë»·¾³×¨Ë¶
+1/72
ÄÏ·½ÓÍУ¡ª¡ª×ÊÔ´Óë»·¾³×¨Ë¶ÕÐÉú£¬»¯Ñ§»·¾³ÉúÎïÀàרҵ¾ù¿É£¬¾ÍÒµºÃ£¬ÓÐרҵ±ÚÀÝ
+1/47
ÑĮ̀´óѧ¾«×¼²ÄÁϸߵÈÑо¿Ôº26Äê²ÄÁÏ·½ÏòÑо¿ÉúÕÐÉú
+1/37
ÉòÑôũҵ´óѧÉúÎïÓëÒ½Ò©ÕÐÊÕµ÷¼ÁÉú£¡£¡£¡£¡£¡£¡£¡£¡£¡£¡
+1/35
Î÷»ª´óѧ²ÄÁÏѧԺ±íÃæ¿ÆÑ§Ó빤³Ì¼¼Êõ¿ÆÑÐÍŶÓ2026ÄêÕÐÊÕÑо¿Éú
+1/33
¡¾211²©Ê¿ÕÐÉú¡¿»·¾³»¯Ñ§¡¢µØÑ§¡¢¶¾Àí·½Ïò£¬Éó¤ÎÛȾÎïÇ¨ÒÆ×ª»¯½µ½â¡¢¼ÆËãÄ£ÄâÕßÓÅÏÈ
+1/33
Öйú¿ÆÑ§ÔºÉϺ£¹èËáÑÎÑо¿ËùÊ©½£ÁÖԺʿÍŶӺúƼ¿ÎÌâ×éÕÐÆ¸²©Ê¿ºó
+1/14
¡¾ÊµÕ½ÐÍ¡¿¡¾ÉúÎïÒ½Ò©¡¿2026Çൺ´óѧÕв©Ê¿Éú º¬ÉÙÊýÃñ×å¹Ç¸É¼Æ»®2Ãû£¡
+1/14
¸£½¨Àí¹¤´óѧ²ÄÁÏѧԺÕÐÊÕ2026˶ʿÑо¿Éú
+1/14
ÖпÆÔººÍ±±¾©¹¤ÉÌ´óѧÕÐÊÕ2026²©Ê¿£¨»¯Ñ§±³¾°£©
+1/13
¡¾2026µ÷¼Á¡¿ÄÏ·½¿Æ¼¼´óѧ-ÉîÛÚÀí¹¤´óѧ-ÖпÆÔº ÁªÅà086000ÃâÒß·½Ïò(26.9Èëѧ)
+1/11
ÖйúµØÖÊ´óѧ£¨Î人£©Çå½àÄÜÔ´Óë×ÊÔ´Ñ»·ÍŶӳÏÕпÆÑÐÖúÀí/2026¼¶Ë¶Ê¿¡¢²©Ê¿Éú/²©Ê¿ºó
+1/5
Î人·ÄÖ¯´óѧÕÐÊÕ˶ʿÑо¿Éúµ÷¼Á £¨ÉçÅ£×îºÃ£©
+1/5
292Çóµ÷¼Á
+1/3
ÉϺ£Ê¦·¶´óѧÓлú»¯Ñ§×¨ÒµÑо¿ÉúÕÐÉú
+1/2
ºþÄÏũҵ´óѧ »·¾³¿ÆÑ§Ó빤³Ì0830+×ÊÔ´Óë»·¾³×¨Ë¶0857 µ÷¼ÁÃû¶î
+1/2
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+4, лл£¬protein stablity shiftÊÇʲôÇé¿ö£¿ 2013-01-06 22:54:33
Сµ¤Ä¾Ä¾: ½ð±Ò+3, ¹ÄÀø½»Á÷ 2013-01-07 16:30:31
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+4, лл£¬protein stablity shiftÊÇʲôÇé¿ö£¿ 2013-01-06 22:54:33
Сµ¤Ä¾Ä¾: ½ð±Ò+3, ¹ÄÀø½»Á÷ 2013-01-07 16:30:31
|
ÄãÕâÆªÎÄÕµÄʵÑéÐԷdz£Ç¿£¬ÓеãÏñС×ÛÊö¡£Éæ¼°µÄ¼¼Êõ½Ï¶à£¬ 1. alpha Screen: http://www.proteomebinders.org/meetings/alpbach/talks/Chevet.pdf 2.A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histonesËùÒÔÊDzⶨ»¯ºÏÎï¶ÔBromodomain»îÐÔµÄÒÖÖÆ×÷Óà 3.ÕâÊÇÑо¿µ°°×½á¹¹ÐÔÖʵķ½·¨£¬¿ÉÒÔÔĶÁ±¾ÎÄhttp://www.ncbi.nlm.nih.gov/pubmed/21674662 4.µÚÈýµã£¬°®ÄªÄÜÖú£¬Ëõд̫¶à£¬¶øÇÒûͼ²»ÄÜÅÐ¶Ï |
2Â¥2013-01-06 14:15:04
ccharlien
ľ³æ (ÕýʽдÊÖ)
- MolEPI: 1
- Ó¦Öú: 82 (³õÖÐÉú)
- ½ð±Ò: 2630.1
- Ìû×Ó: 334
- ÔÚÏß: 180.3Сʱ
- ³æºÅ: 1168776
¡ï ¡ï ¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл 2013-01-06 22:54:27
Сµ¤Ä¾Ä¾: ½ð±Ò+2, ¹ÄÀø½»Á÷ 2013-01-07 16:30:47
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл 2013-01-06 22:54:27
Сµ¤Ä¾Ä¾: ½ð±Ò+2, ¹ÄÀø½»Á÷ 2013-01-07 16:30:47
|
3. ʵÑéÊÒÀïKAc Ò»°ãÊÇ´×Ëá¼ØµÄËõд£¨Potassium acetate£©£¬Ã»ÓÐÉÏÏÂÎÄ£¬²»È·¶¨ RLUsÒ»°ãÊÇRelative Luciferase UnitsµÄËõд Dose¾ÍÊÇÊÔ¼ÁµÄ¼ÁÁ¿ ¿´ÆðÀ´ÊÇÓÃÁËÒ»¸ö±¨¸æ»ùÒòÊÔÑéÖ¤Ã÷¼ÁÁ¿¶Ô»îÐԸıäµÄÓ°Ïì |
3Â¥2013-01-06 20:57:27
¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл£¡Âé·³½üÁ½Ìì¹Ø×¢ÎÒÔÚÉúÎï°å¿éµÄÆäËûÇóÖúÌû£¬¹ØÓÚ·Ö×Ó¶Ô½ÓµÄ 2013-01-07 13:09:30
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл£¡Âé·³½üÁ½Ìì¹Ø×¢ÎÒÔÚÉúÎï°å¿éµÄÆäËûÇóÖúÌû£¬¹ØÓÚ·Ö×Ó¶Ô½ÓµÄ 2013-01-07 13:09:30
| KAc, ÄãµÃ¿´¿´ÎÄÖÐÊÇ·ñÏà·û¡£ÎÒ¸øÄãµÄÎÄÏ×ÓÐһƪ¾ÍÊÇ×östability shift¡£ ÀýÈ磬ÄãÓÃÈȱäÐÔÀ´¿¼²ìµ°°×Îȶ¨ÐÔ£¬ ÓÉÓÚÌõ¼þµÄ¸Ä±ä£¬¼Óµ×Î µÃµ½µÄÇúÏßÓëÎÞµ×ÎïµÄ¾Í²»Ò»Ö¡£Õâ¾ÍÊÇÎȶ¨ÐÔÆ¯ÒÆ£¡ |
4Â¥2013-01-07 09:03:57
5Â¥2013-01-07 12:48:27
¼òµ¥»Ø¸´
tianyiliang36Â¥
2013-04-20 15:05
»Ø¸´














»Ø¸´´ËÂ¥